Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

60 Degrees Pharmaceuticals (SXTP) Total Debt (2022 - 2025)

Historic Total Debt for 60 Degrees Pharmaceuticals (SXTP) over the last 4 years, with Q3 2025 value amounting to $797275.0.

  • 60 Degrees Pharmaceuticals' Total Debt rose 2781.72% to $797275.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $797275.0, marking a year-over-year increase of 2781.72%. This contributed to the annual value of $640830.0 for FY2024, which is 7221.99% down from last year.
  • Per 60 Degrees Pharmaceuticals' latest filing, its Total Debt stood at $797275.0 for Q3 2025, which was up 2781.72% from $776172.0 recorded in Q2 2025.
  • 60 Degrees Pharmaceuticals' 5-year Total Debt high stood at $24.8 million for Q2 2023, and its period low was $565949.0 during Q1 2024.
  • For the 4-year period, 60 Degrees Pharmaceuticals' Total Debt averaged around $3.3 million, with its median value being $776172.0 (2025).
  • As far as peak fluctuations go, 60 Degrees Pharmaceuticals' Total Debt crashed by 9770.98% in 2024, and later soared by 3687.89% in 2025.
  • Over the past 4 years, 60 Degrees Pharmaceuticals' Total Debt (Quarter) stood at $2.6 million in 2022, then decreased by 11.41% to $2.3 million in 2023, then plummeted by 72.22% to $640830.0 in 2024, then grew by 24.41% to $797275.0 in 2025.
  • Its Total Debt stands at $797275.0 for Q3 2025, versus $776172.0 for Q2 2025 and $635725.0 for Q1 2025.